12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MGCD290: Phase I data

Data from 4 double-blind, placebo-controlled Phase I trials showed that single and multiple ascending-doses of once-daily MGCD290 were generally well tolerated with no serious adverse events reported. The 290-001 trial evaluated single ascending-doses of 100-1,000 mg MGCD290 in 56 healthy volunteers. The...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >